Anti-Mouse CD49d – Purified in vivo GOLD™ Functional Grade
Anti-Mouse CD49d – Purified in vivo GOLD™ Functional Grade
Product No.: C620
Clone R1-2 Target CD49D Formats AvailableView All Product Type Hybridoma Monoclonal Antibody Alternate Names VLA-4 α chain, integrin α4, ITGA4 Isotype Rat IgG2b κ Applications FA , FC , IHC , IP |
Antibody DetailsProduct DetailsReactive Species Mouse Host Species Rat Recommended Isotype Controls Recommended Dilution Buffer Immunogen AKR/Cum mouse Spontaneous T lymphoma line TK1 Product Concentration ≥ 5.0 mg/ml Endotoxin Level ≤ 1.0 EU/mg as determined by the LAL method Purity ≥95% by SDS Page ⋅ ≥95% monomer by analytical SEC Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. State of Matter Liquid Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Regulatory Status Research Use Only Country of Origin USA Shipping 2-8°C Wet Ice Additional Applications Reported In Literature ? FA, IHC-F, IP, FC Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity R1-2 activity is directed against mouse CD49d. Background Integrins are a large family of heterodimeric transmembrane molecules that mediate adhesion, migration, cell survival, and cell differentiation. CD49d is a single-pass type I membrane glycoprotein also known as integrin alpha-4 (Uniprot Accession P13612). CD49d is the α4 subunit of integrin heterodimers alpha-4/beta-1 (VLA-4; CD49d/CD29; α4β1 integrin) and alph-4/beta-7 (LPAM-1)1. These integrins act as receptors for fibronectin and VCAM1 (CD106). Integrin alpha-4/beta-7 is also a receptor for MADCAM1. CD49d is expressed on most lymphocytes, granulocytes, monocytes, and thymocytes. CD49d/CD29 (VLA-4; α4β1) is expressed at high levels on the surface of lymphohematopoietic progenitors and is involved in their development and proliferation. CD49d/CD29 integrin/VCAM-1 interactions facilitate B cell adhesion to stromal cells and enhance B cell activation. In the absence of alpha-4 integrins, pre-B cells fail to transmigrate and proliferate. R1-2 was generated by immunizing Fisher rats with TK1, a Peyer’s patch high endothelial venules (HEV) binding lymphoma line2. Spleen cells were subsequently fused with nonsecreting mouse myeloma P3x63Ag8.653 cells. Hybridomas producing antibodies reactive with TK1 cells, but not the HEV nonbinding lymphoma TK5, were cloned and screened for inhibition of lymphocyte binding to HEV of either peripheral nodes or Peyer’s patches. Antigen Distribution CD49d is expressed on T cells, B cells, NK cells, dendritic cells, thymocytes, monocytes, eosinophils, mast cells. Ligand/Receptor VCAM-1, MAdCAM-1, fibronectin NCBI Gene Bank ID UniProt.org Research Area Cell Adhesion . Immunology Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Clone R1-2, which targets CD49d (Integrin α4), is commonly used in vivo in mice for blocking cell-cell adhesion interactions and T cell costimulation. Its main in vivo applications are focused on functional modulation of the integrin α4 pathway, most notably to interfere with leukocyte trafficking and immune responses. Key in vivo applications include:
Additional details:
Summary Table: Common in vivo uses for clone R1-2 in mice
There is no evidence in the provided results of in vivo cell depletion with clone R1-2 (its main action is blocking, not depleting/leukotoxic), nor is it primarily used as a general in vivo imaging reagent. Its functionally validated and reported in vivo role is adhesion and costimulation blockade relevant to immune cell trafficking and pathophysiology in murine models of disease. Commonly used antibodies or proteins with R1-2 in the literature often depend on the specific research context, but they typically include other antibodies targeting related epitopes, isotype controls, or proteins implicated in similar biological pathways.
Summary of commonly used antibody or protein co-targets:
If the specific target of “R1-2” refers to a particular antigen or protein in a unique context (such as cancer immunity, viral neutralization, or receptor biology), the accompanying antibodies or proteins will be tailored accordingly. The prevailing pattern in literature is the use of dual or multiple antibodies to maximize experimental or therapeutic outcomes. The key findings involving clone R1-2 in scientific literature focus on its use in genetic and protein studies, particularly in disease modeling, evolutionary biology, and protein function characterization.
These citations demonstrate that clone R1-2 is frequently referenced as a model system or representative sequence/variant in advanced genome editing, evolutionary tracking of protein features, and as a tool for quantifying the functional consequences of specific genetic changes. Both sources provide clear examples of how clone R1-2 serves as a foundation for mechanistic and comparative studies in biomedical and molecular research. Dosing regimens for clone R1-2 (an anti-mouse CD49b antibody used chiefly for NK cell depletion) are typically standardized, but can vary depending on the specific mouse model, the experimental application (e.g., tumor models, infection, autoimmunity), and desired duration or depth of NK cell depletion. Search results provided do not give direct dosing information for clone R1-2 specifically, but standard approaches for functional antibodies in mouse models can be inferred from comprehensive antibody dosing guides. Key points on dosing regimens (with context from analogous depletion antibodies):
Additional considerations:
Summary Table: Standard Dosing for Depleting Antibodies in Mouse Models
The actual dosing for clone R1-2 in published studies generally follows these conventions, but always confirm dosing with the most relevant literature for your disease model and experimental design, or conduct a pilot study for optimization. Adjustment in dose or schedule may be required depending on the mouse strain, age, immune status, and in vivo depletion efficiency measured by flow cytometry. No search result directly addresses R1-2 dosing variability, so these recommendations are grounded in standard practices and analogous protocols for other cell-depleting antibodies in mice. References & Citations1. Holzmann B, Weissman IL. EMBO J. 8(6):1735-1741. 1989. 2. Holzmann B, McIntyre BW, Weissman IL. Cell. 56(1):37-46. 1989. 3. Jin H, Aiyer A, Su J, et al. J Clin Invest. 116(3):652-662. 2006. 4. DeNucci CC, Pagán AJ, Mitchell JS, et al. J Immunol. 184(5):2458-2467. 2010. 5. Uchida Y, Kawai K, Ibusuki A, et al. J Immunol. 186(12):6945-6954. 2011. 6. Hadeiba H, Lahl K, Edalati A, et al. Immunity. 36(3):438-450. 2012. 7. Shokeen M, Zheleznyak A, Wilson JM, et al. J Nucl Med. 53(5):779-786. 2012. 8. Renkema KR, Li G, Wu A, et al. J Immunol. 192(1):151-159. 2014. 9. Hermida MD, Doria PG, Taguchi AM, et al. BMC Infect Dis. 14:450. 2014. 10. Mamedov MR, Scholzen A, Nair RV, et al. Immunity. 48(2):350-363.e7. 2018. 11. Rolot M, Dougall AM, Chetty A, et al. Nat Commun. 9(1):4516. 2018. 12. Martin MD, Sompallae R, Winborn CS, et al. Cell Rep. 31(2):107508. 2020. 13. Müller K, Gibbins MP, Roberts M, et al. EMBO Mol Med. 13(4):e13390. 2021. 14. Barrett SP, Riordon A, Toh BH, et al. J Leukoc Biol. 67(2):169-173. 2000. 15. Lin J, Qin L, Chavin KD, et al. Pathobiology. 63(3):119-132. 1995. 16. Chisholm PL, Williams CA, Lobb RR. Eur J Immunol. 23(3):682-688. 1993. Technical ProtocolsCertificate of Analysis |
Formats Available
Prod No. | Description |
---|---|
C625 | |
C624 | |
C622 | |
C623 | |
C626 | |
C630 | |
C631 | |
C632 | |
C620 | |
C621 |
